The ELCAP Stage I Survival Framework

92% 10-year lung cancer-specific survival when stage I disease got prompt surgical resection. 🎯
That number, from I-ELCAP’s 2006 New England Journal of Medicine report, is the entire argument for low-dose CT screening in one stat.

According to The ASCO Post, the I-ELCAP program screened 31,567 people and identified 484 lung cancers. 85% of those were clinical stage I. The estimated 10-year lung cancer-specific survival for stage I patients was 88% overall. Among those who underwent prompt surgical resection, it hit 92%.

That is not incremental. That is the difference between a fatal disease and a curable one.

The original ELCAP findings, published in The Lancet in 1999, showed that low-dose CT detected substantially more early lung cancers than chest radiography. Claudia Henschke started that work in 1992. It took over a decade of scientific argument before the field accepted the proposition.

Then the National Lung Screening Trial settled it. More than 53,000 high-risk people were randomized to low-dose CT or chest radiography. CT screening reduced lung cancer mortality. A randomized trial confirmed what the observational data had been showing for years.

Save this. Share it with your MDT.

The ELCAP Stage I Survival Framework:

🔹 Screen the right population with low-dose CT, using validated eligibility criteria
🔹 Achieve Lung-RADS categorization with clear documentation for every finding
🔹 Separate incidental findings from actionable nodules immediately
🔹 Route confirmed or highly suspicious stage I lesions toward prompt surgical evaluation
🔹 Track time-to-surgery as a program quality metric, not just a case detail
🔹 Report stage distribution at program level quarterly, 85% stage I is the benchmark from I-ELCAP

The word prompt matters. I-ELCAP did not just find cancer early. It moved patients to resection quickly. The 92% survival figure is inseparable from that speed.

Most screening programs track volumes and completion rates. Fewer track the time between a positive screen and a surgical consult. That gap in measurement is where survival outcomes quietly erode.

Thirty years of evidence, from Henschke’s first ELCAP results to the NLST randomized trial, points to the same conclusion. Lung cancer is curable at stage I. The imaging infrastructure to find it exists. The bottleneck is almost never the scan. It is the pathway from scan result to surgeon.

If your program cannot answer how long that pathway takes, you are optimizing the wrong thing.

👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on LinkedIn: https://www.linkedin.com/newsletters/the-oatmeal-bite-7368331304385314817/